ReviewNanomedicine (London, England)2025
Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- ROS-Responsive Nanoparticle Delivery of Dexmedetomidine Protects the Gut Vascular Barrier After Intestinal Ischemia/Reperfusion via the HDAC-H3K27ac-TCF4 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- Tumor Microenvironment-Responsive Polymeric Nanocarriers for the Treatment of Triple-Negative Breast Cancer.Pharmaceutics · 2026Review
- Next-Generation Nanocarrier Platforms for RNA Vaccines: Advances in Formulation, Stability Engineering, and Translational Manufacturing Challenges.Pharmaceutics · 2026Review
- Emerging paradigms in nanostructured targeted drug delivery systems.Discover nano · 2026Review
- Circular RNA as emerging precision therapeutics: from RNA regulation to peptide translation.Precision clinical medicine · 2026Review
- Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As the healthcare landscape rapidly evolves to include advanced drug delivery methods with better cellular targeting and more efficient delivery, polymeric nanocarriers have emerged to close translational gaps. Acting on the central dogma of molecular biology, mRNA and protein therapeutics can offer curative potential for various debilitating diseases. Considering these advancements, polymeric nanocarriers have been widely explored preclinically in delivering both proteins and mRNA for various disease therapies. This review introduces how the next generation of polymeric nanocarriers can be designed for protein therapeutics, including some advantages and disadvantages as well as specific design considerations for mRNA vs protein delivery. The evolution of these polymeric nanocarriers is then examined, and the current landscape and emerging trends are presented. Finally, we provide an outlook on the clinical translation of polymeric nanocarrier delivery of mRNA and proteins, including a future perspective for the field. Despite the preclinical promise of these delivery systems in both mRNA and protein constructs, clinical translation is underwhelming. Continued development of polymeric nanocarriers is underway and early clinical trials have provided a foothold into translation for this technology. A key challenge for polymeric nanomedicine is bridging the gap between promising preclinical data and successful clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.